Osimertinib, a novel targeted therapy, has emerged as a groundbreaking treatment option for glioblastoma, a highly aggressive and challenging form of brain cancer. By specifically targeting the EGFR (epidermal growth factor receptor) mutation, osimertinib offers a personalized approach to managing glioblastoma, providing hope for patients who have exhausted other treatment options. This article...